Drug intelligence / Profile preview

evorpacept + rituximab + lenalidomide

Development stage: Unknown
Lead developer: ALX Oncology
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

Evorpacept (ALX148) is a high-affinity signal regulatory protein alpha (SIRPα) fusion protein designed to block the CD47 checkpoint on cancer cells, thereby neutralizing the 'do-not-eat-me' signal and enabling macrophage-mediated phagocytosis. In this specific clinical context at M.D. Anderson Cancer Center, evorpacept is being evaluated in an investigator-initiated Phase I/II trial (NCT05025800) in combination with rituximab, a CD20-targeting monoclonal antibody, and lenalidomide, an immunomodulatory imide drug (IMiD). This triplet combination therapy is intended to treat patients with various subtypes of B-cell non-Hodgkin lymphoma, including follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, by leveraging the synergistic effects of CD47 blockade, antibody-dependent cellular cytotoxicity (ADCC), and immunomodulation to enhance anti-tumor immune responses.

Brand names: RituxanRevlimid
Other names: ALX148 + Rituximab + LenalidomideCD47 Antagonist ALX148 + Rituximab + Lenalidomide

Targets

SIRPA (Signal-regulatory protein alpha)CD47 (Cluster of Differentiation 47)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)

Beyond the preview

Go deeper on evorpacept + rituximab + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on evorpacept + rituximab + lenalidomide.

Explore the full profile